Kailera Therapeutics, Inc. (KLRA)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2026-Mar-31
Fiscal PeriodQ1-FY2026
Total Revenue
QoQ%
YoY%
Cost Of Revenue
Gross Profit
Gross Margin
Operating Expenses84,660,000$20,458,000$
Operating Income(84,660,000$)(20,458,000$)
Operating Margin
Interest Income5,716,000$1,675,000$
Interest Expenses0$0$
Income Before Tax(78,865,000$)(17,983,000$)
Tax Expenses
Net Income(78,865,000$)(17,983,000$)
Profit Margin
TTM
Earnings to Minority
Earnings to Common Shareholders(78,865,000$)(17,983,000$)
QoQ%
YoY%(338.55%)
Earnings Per Share, Basic(3,649.97$)(17,983,000.00$)
Earnings Per Share, Diluted(3,649.97$)(17,983,000.00$)
Unlevered FCF Per Share, Basic(3,161.48$)(18,201,000.00$)
Unlevered FCF Per Share, Diluted(3,161.48$)(18,201,000.00$)
Average Shares, Basic21,6071
Average Shares, Diluted21,6071
EBIT(78,865,000$)(17,983,000$)
EBITDA(78,764,000$)(17,920,000$)